Subtopic Deep Dive
HER2 Amplification Prognosis
Research Guide
What is HER2 Amplification Prognosis?
HER2 amplification prognosis assesses the correlation between HER2 gene overexpression, detected via FISH or IHC assays, and adverse clinical outcomes including tumor aggressiveness, relapse risk, and reduced survival in breast and other cancers.
HER2 amplification drives aggressive tumor behavior, guiding targeted therapies like trastuzumab (Vucicevic et al., 2013, 4416 citations). Clinical guidelines integrate HER2 status for diagnosis and follow-up in primary breast cancer (Aebi et al., 2010, 2860 citations). Over 10 key papers from 2004-2022 link HER2/EGFR alterations to prognosis and treatment response.
Why It Matters
HER2 amplification identifies patients for trastuzumab therapy, improving survival in HER2-positive breast cancer from 56.5 months with pertuzumab combinations (Swain et al., 2015). FISH-detected high EGFR copy number predicts gefitinib response in NSCLC, enabling personalized treatment (Cappuzzo et al., 2005). Accurate prognostication via HER2 status refines risk stratification, avoiding overtreatment in node-negative cases (Sparano et al., 2015).
Key Research Challenges
Heterogeneity in HER2 Assays
Variability between FISH and IHC methods complicates consistent HER2 amplification detection across tumor samples (Iqbal et al., 2014). Standardization remains critical for reliable prognosis (Aebi et al., 2010). Discrepancies impact therapy eligibility.
Prognostic Signature Integration
Combining HER2 with 21-gene assays for precise risk prediction in HER2-negative cases challenges model accuracy (Sparano et al., 2015). Multi-omic integration heightens complexity (Sigismund et al., 2017). Validation across cohorts is limited.
Therapy Resistance Prediction
HER2-targeted therapies like trastuzumab face resistance linked to downstream signaling (Vucicevic et al., 2013). EGFR co-amplification predicts poor response in NSCLC (Cappuzzo et al., 2005). Biomarker panels for relapse risk need refinement.
Essential Papers
Trastuzumab-Induced Hepatotoxicity: A Case Report
D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin · 2013 · Breast Care · 4.4K citations
<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are...
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber et al. · 2010 · Annals of Oncology · 2.9K citations
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · 2015 · New England Journal of Medicine · 2.0K citations
In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall...
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi et al. · 2005 · JNCI Journal of the National Cancer Institute · 1.6K citations
High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, Robert J. Gray, Della Makower et al. · 2015 · New England Journal of Medicine · 1.4K citations
Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of cli...
Emerging functions of the <scp>EGFR</scp> in cancer
Sara Sigismund, Daniele Avanzato, Letizia Lanzetti · 2017 · Molecular Oncology · 1.4K citations
The physiological function of the epidermal growth factor receptor ( EGFR ) is to regulate epithelial tissue development and homeostasis. In pathological settings, mostly in lung and breast cancer ...
Review of epidermal growth factor receptor biology
Roy S. Herbst · 2004 · International Journal of Radiation Oncology*Biology*Physics · 1.4K citations
Reading Guide
Foundational Papers
Start with Vucicevic et al. (2013) for trastuzumab in HER2-amplified breast cancer basics (4416 citations), then Aebi et al. (2010) ESMO guidelines for clinical prognostication protocols.
Recent Advances
Study Swain et al. (2015) for pertuzumab survival extension to 56.5 months and Sigismund et al. (2017) for emerging EGFR/HER2 functions in tumor progression.
Core Methods
Core techniques include FISH for gene copy number (Cappuzzo et al., 2005), IHC for overexpression, and 21-gene assays for risk stratification (Sparano et al., 2015).
How PapersFlow Helps You Research HER2 Amplification Prognosis
Discover & Search
Research Agent uses searchPapers('HER2 amplification prognosis FISH IHC breast cancer') to retrieve top papers like Vucicevic et al. (2013), then citationGraph reveals 4416 citing works on trastuzumab outcomes, while findSimilarPapers expands to Swain et al. (2015) for survival data.
Analyze & Verify
Analysis Agent applies readPaperContent on Aebi et al. (2010) guidelines, then verifyResponse with CoVe cross-checks FISH/IHC concordance claims against Cappuzzo et al. (2005), and runPythonAnalysis computes meta-analysis survival odds ratios using GRADE for high-evidence prognostic claims.
Synthesize & Write
Synthesis Agent detects gaps in resistance biomarkers post-trastuzumab, flags contradictions between IHC/FISH in Iqbal et al. (2014), while Writing Agent uses latexEditText for prognostic tables, latexSyncCitations for 10-paper bibliography, and latexCompile for publication-ready review.
Use Cases
"Extract survival data from HER2 amplification papers and compute pooled hazard ratios."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on HRs from Vucicevic 2013, Swain 2015) → CSV export of forest plot statistics.
"Draft LaTeX review on HER2 FISH prognosis in breast cancer guidelines."
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Aebi 2010 et al.) → latexCompile → PDF with integrated figures.
"Find code for HER2 genomic analysis from related papers."
Research Agent → paperExtractUrls (Sparano 2015) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on shared scripts for gene signature simulation.
Automated Workflows
Deep Research workflow scans 50+ HER2 papers via searchPapers → citationGraph → DeepScan 7-step verification with CoVe on assay concordance (Cappuzzo 2005). Theorizer generates hypotheses on HER2-EGFR co-amplification resistance from Sigismund et al. (2017) via gap detection → mermaid survival diagrams.
Frequently Asked Questions
What defines HER2 amplification prognosis?
HER2 amplification prognosis links FISH/IHC-detected overexpression to higher relapse and lower survival rates, as in breast cancer guidelines (Aebi et al., 2010).
What are key methods for HER2 assessment?
FISH quantifies gene copy number for prognosis prediction (Cappuzzo et al., 2005), while IHC measures protein overexpression; both guide trastuzumab use (Vucicevic et al., 2013).
What are foundational papers?
Vucicevic et al. (2013, 4416 citations) details trastuzumab in HER2-amplified cases; Aebi et al. (2010, 2860 citations) provides ESMO guidelines; Herbst (2004) reviews EGFR biology.
What open problems exist?
Integrating HER2 with multi-gene signatures for resistance prediction remains unsolved (Sparano et al., 2015); assay standardization across cancers persists (Iqbal et al., 2014).
Research HER2/EGFR in Cancer Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HER2 Amplification Prognosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the HER2/EGFR in Cancer Research Research Guide